Syndax Announces Participation at Two Upcoming Investor Conferences

February 1, 2024

WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:

  • A fireside chat at the Guggenheim 6th Annual Biotechnology Conference at 10:00 a.m. ET on Thursday, February 8, 2024 in New York, NY.
  • A fireside chat at the Citi 2024 Virtual Oncology Leadership Summit at 2:00 p.m. ET on Wednesday, February 21, 2024.

A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at, where a replay of the events will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
Tel 781.684.9827


Cision View original content:

SOURCE Syndax Pharmaceuticals, Inc.